Abstract
Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)–modified T cells are a promising new treatment, and at JADPRO Live Virtual 2021, presenters compared pivotal trials in CAR T-cell therapy for multiple myeloma, discussed how to recognize and manage common toxicities after CAR T-cell infusion, and reviewed pre-CAR-T consultation and post-CAR-T management.
